

Classification	ESG Policy	ESG Information Announcement Policy	Rev. Date	08. 2022
Page	1		Rev. No.	0.2

SK Biopharmaceuticals manages environmental, social, and governance data in a transparent way, and announces the influence of various ESG risks on strategic, financial, and business in accordance with the TCFD, SASB, and GRI Standards guidelines.

SK Biopharmaceuticals' Sustainability Report will comply with the core options of the Global Reporting Initiative (GRI) Standards, which is an international reporting guideline. Financial information is announced based on separate financial statements, and the reporting standards and definitions follow the K-IFRS. Both financial information and non-financial information are based on the fiscal year.

SK Biopharmaceuticals has a target to announce the current status of each ESG topic demanded by the pharmaceutical industry in accordance with the Sustainability Accounting Standards Board (SASB), which is a global sustainability reporting standard. According to the Taskforce on Climate-related Financial Disclosure (TCFD), SK Biopharmaceuticals set a goal to announce the impact of climate change on businesses and counteractions in the Sustainability Report.

The 2022 Sustainability Report of SK Biopharmaceuticals contains the following matters:

- Statement of reporting standards for the Sustainability Report on P.78;
- Announcement of SK Biopharmaceuticals' data according to the SASB on P.68-70;
- Announcement of SK Biopharmaceuticals' data according to the TCFD on P.71-72; and
- Preparation of the Sustainability Report according to the GRI on P.73-74.